Intellectual Property Rights (TRIPS Agreement) and Access to Medicines: Conflict of Interest between Western Pharmaceutical Giants and Developing Countries

Abstract

Introduction: The intersection of intellectual property rights and access to medicines constitutes one of the most critical and contentious challenges in contemporary global health. The impact of the TRIPS Agreement (Trade-Related Aspects of Intellectual Property Rights) is particularly acute in developing nations, where a significant portion of the population lives under conditions of limited access to life-saving medicines. This study aims to provide a comprehensive analysis of the interrelation between the TRIPS Agreement, the pharmaceutical patent system, and access to essential medicines, while highlighting the conflict of interest between Western pharmaceutical corporations and developing countries. Methodology: This research synthesizes and analyzes reports from international organizations, academic literature, World Trade Organization documents, and existing empirical evidence in the field of global health. Utilizing a qualitative research design, the study employs comparative analysis and specific case studies, including the HIV/AIDS crisis in sub-Saharan Africa and the international debates surrounding COVID-19 vaccines.  Results: The findings demonstrate that the TRIPS Agreement has significantly strengthened the position of Western pharmaceutical companies and tightened international standards for patent protection on medicines. While this framework has incentivized pharmaceutical innovation and the development of new drugs, it has simultaneously created severe barriers for developing countries regarding access to affordable generic medicines. The paper argues that patent monopolies frequently lead to artificial inflation of drug prices, geographical restrictions on treatment, and adverse public health outcomes. Furthermore, the analysis reveals that the flexibilities embedded within the TRIPS Agreement, such as compulsory licensing, serve as vital instruments for protecting public health, although their practical implementation is often hindered by political and economic pressures. Conclusion: Ensuring equitable access to medicines requires the establishment of a more just and balanced international system that simultaneously protects pharmaceutical innovation and the fundamental human right to health. Achieving this objective is unattainable without deepening international cooperation, enhancing technology transfer, optimizing regulatory mechanisms, and providing more effective legal protection for the interests of developing nations. The study underscores that global health security depends on coordinated and solidary collaboration among states, international organizations, the pharmaceutical industry, and civil society.